Caris Life Sciences, Inc.
CAI
$38.39
-$0.09-0.23%
NASDAQ
| 06/30/2025 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Net Income | 30.02% | 40.39% | |||
| Total Depreciation and Amortization | -9.03% | -34.43% | |||
| Total Amortization of Deferred Charges | 298.71% | 8.93% | |||
| Total Other Non-Cash Items | 35.60% | -131.41% | |||
| Change in Net Operating Assets | -110.80% | -247.72% | |||
| Cash from Operations | 123.26% | 14.88% | |||
| Capital Expenditure | 48.46% | -48.91% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -100.00% | |||
| Cash from Investing | 48.46% | -104.34% | |||
| Total Debt Issued | -- | -100.00% | |||
| Total Debt Repaid | 0.00% | 62.50% | |||
| Issuance of Common Stock | 36,835.08% | 87.14% | |||
| Repurchase of Common Stock | -7,436.36% | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | 4,223.81% | -- | |||
| Cash from Financing | 52,927.39% | -100.06% | |||
| Foreign Exchange rate Adjustments | 2,225.00% | 1,100.00% | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 2,199.69% | -135.32% | |||